Labels over-the-counter use of electrocardiograph software devices as Class II (special controls), which requires manufactures to conduct hazard analysis of detection algorithms in the devices.
Analysis summaries, actor details, and coverage mappings were LLM-classified and may contain errors.
This is a binding federal regulation from the FDA with mandatory requirements for manufacturers, including specific testing, validation, and labeling obligations that must be met for Class II medical device classification.
The document has minimal coverage of approximately 2-3 subdomains, with focus on AI system safety failures (7.3 Lack of robustness) and human-computer interaction risks (5.1 Overreliance and unsafe use). Coverage is concentrated in technical reliability and user interaction safety domains.
The regulation primarily governs the Health Care and Social Assistance sector, specifically medical device manufacturers developing AI-based diagnostic software. It also has implications for the Information sector (software development) and Scientific Research and Development Services (clinical testing).
The document covers multiple AI lifecycle stages with primary focus on verification/validation, deployment preparation, and operational monitoring. It addresses design requirements, model validation, deployment readiness through labeling, and post-deployment user interaction monitoring.
The document explicitly addresses AI systems (electrocardiograph software devices) and AI models (detection algorithms). It focuses on task-specific, predictive AI for cardiac arrhythmia detection. No mention of frontier AI, general purpose AI, foundation models, generative AI, open-weight models, or compute thresholds.
Food and Drug Administration (FDA)
The document is a federal regulation (21 CFR § 870.2345) issued by the FDA under its regulatory authority over medical devices.
Food and Drug Administration (FDA)
The FDA has enforcement authority over medical devices through its regulatory powers, including the ability to require compliance with Class II special controls and take enforcement action against non-compliant manufacturers.
Food and Drug Administration (FDA)
The FDA monitors compliance with medical device regulations through pre-market review, post-market surveillance, and inspection of manufacturers to ensure adherence to special controls.
The regulation applies to manufacturers of electrocardiograph software devices for over-the-counter use, who must develop and deploy these AI-based medical devices in compliance with the special controls specified.
3 subdomains (2 Good, 1 Minimal)